Company News, Patents

Codex Labs Earns Fifth US Patent for Skincare Technology

Patent No. 11,484,489 relates to brand's ShaantComplex.

Author Image

By: Christine Esposito

Editor-in-Chief

Codex Labs Corporation has been granted a new US patent directed to compositions and methods of managing acne-causing excess sebum production and concurrent inflammation related to its ShaantComplex.

Patent No. 11,484,489 is entitled “Skin Care Compositions and Methods for Regulating Seubm Production.”

The ShaantComplex is composed of four plant actives, namely, Tetraselmis chuii, Fucus spiralis, Centella asiatica and Pogostemon Cablin. Gene expression testing performed on individual actives, as well as the ShaantComplex itself, showed that the complex possessed enhanced bioactivity in its ability to positively influence oily skin disorders. The functionality of the complex was further validated in formulated products via clinical testing under the supervision of a board-certified dermatologist, wherein the data revealed a decrease in excess sebum, acne formation and redness, without de-hydration, according to the company.

This latest patent increases the company's portfolio to five US patents.

“We are thrilled the US Patent and Trademark Office has acknowledged our newest plant biotech-based ShaantComplex technology,” said Dr. Barbara Paldus, founder and CEO, Codex Labs Corporation. “We've spent significant R&D resources developing our Bia, Antü, and Shaant  lines, and are grateful to see our hard work come to fruition through this acknowledgement of our innovative technologies.”

You can learn more about the development of the ShaantComplex in this recent Happi.com feature on novel ingredients in skincare.

Keep Up With Our Content. Subscribe To Happi Newsletters